CORDIS
EU research results

CORDIS

English EN
High-throughput peptidomics and transcriptomics of animal venoms for discovery of novel therapeutic peptides and innovative drug development

High-throughput peptidomics and transcriptomics of animal venoms for discovery of novel therapeutic peptides and innovative drug development

Objective

Animal venoms are complex cocktails of peptides that have enormous potential as novel therapeutic leads. Replicating in vitro the diversity of venoms by generating large synthetic combinatorial peptide libraries will solve the challenge of working with limited amounts of natural products and permit high-throughput investigation of their pharmacology. A new investigation paradigm associating transcriptomics and proteomics is the only way to achieve this goal and to address the complexity of this unexplored 40,000,000 peptide resource. The vision of the VENOMICS project is to develop, integrate and implement cutting-edge and innovative technologies in a high-throughput approach to investigate the enormous structural and pharmacological diversity of venom peptides. We will use the largest venom and venom gland collection in the world to generate a comprehensive sequence database of bioactive peptides, and produce a 10,000 reticulated peptide bank to be used in drug discovery efforts and development of novel therapeutics. A 1000-fold improvement in throughput over the current situation (1 to 2 candidates generated per year) is reasonably foreseen.
Implementation of the project will require both improvements and the integration of exisiting technologies in a high-throughput workflow comprising venom and tissue sourcing, mass spectrometry-based automated de novo peptide sequencing, transcriptomics of venom gland-derived RNA or cDNA/EST libraries, bioinformatics, implementation of a sequence database, and highly parallel synthetic or recombinant production including peptide refolding. The last step will be the validation of the approach in functional assays targeting specific pathologies. VENOMICS is a high-impact project with societal (new drugs against life threatening diseases), scientific and technological (filling the drug discovery pipeline), political (European leadership in the field) and economic (new opportunities for the biologics market) benefits.

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

Address

Rue Leblanc 25
75015 Paris 15

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 319 885,36

Administrative Contact

Nicolas Gilles (Dr.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE DE LA MEDITERRANEE D'AIX-MARSEILLE II

France

EU Contribution

€ 1 280,38

VENOMETECH SAS

France

EU Contribution

€ 373 912,96

SISTEMAS GENOMICOS SL

Spain

EU Contribution

€ 1 185 049,60

NZYTECH LDA

Portugal

EU Contribution

€ 737 800

ABSISKEY CP

France

EU Contribution

€ 159 000

ZEALAND PHARMACEUTICALS AS

Denmark

EU Contribution

€ 344 400

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 836 887,35

UNIVERSITE DE LIEGE

Belgium

EU Contribution

€ 1 040 571

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

Project information

Grant agreement ID: 278346

Status

Closed project

  • Start date

    1 November 2011

  • End date

    31 October 2015

Funded under:

FP7-HEALTH

  • Overall budget:

    € 9 360 275,25

  • EU contribution

    € 5 998 786,65

Coordinated by:

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France